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ABSTRACT
Low-grade gliomas are one of the most common brain tumors in children, where 
they frequently form within the optic pathway (optic pathway gliomas; OPGs). 
Since many OPGs occur in the context of the Neurofibromatosis Type 1 (NF1) cancer 
predisposition syndrome, we have previously employed Nf1 genetically-engineered 
mouse (GEM) strains to study the pathogenesis of these low-grade glial neoplasms. 
In the light of the finding that human and mouse low-grade gliomas are composed of 
Olig2+ cells and that Olig2+ oligodendrocyte precursor cells (OPCs) give rise to murine 
high-grade gliomas, we sought to determine whether Olig2+ OPCs could be tumor-
initiating cells for Nf1 optic glioma. Similar to the GFAP-Cre transgenic strain previously 
employed to generate Nf1 optic gliomas, Olig2+ cells also give rise to astrocytes in the 
murine optic nerve in vivo. However, in contrast to the GFAP-Cre strain where somatic 
Nf1 inactivation in embryonic neural progenitor/stem cells (Nf1flox/mut; GFAP-Cre mice) 
results in optic gliomas by 3 months of age in vivo, mice with Nf1 gene inactivation 
in Olig2+ OPCs (Nf1flox/mut; Olig2-Cre mice) do not form optic gliomas until 6 months of 
age. These distinct patterns of glioma latency do not reflect differences in the timing 
or brain location of somatic Nf1 loss. Instead, they most likely reflect the cell of origin, 
as somatic Nf1 loss in CD133+ neural progenitor/stem cells during late embryogenesis 
results in optic gliomas at 3 months of age. Collectively, these data demonstrate that 
the cell of origin dictates the time to tumorigenesis in murine optic glioma.
INTRODUCTION
Low-grade glial neoplasms (pilocytic 
astrocytoma; PA) account for the majority of brain tumors 
in children between the ages of five and fifteen. In contrast 
to adult high-grade gliomas, low-grade gliomas in children 
typically arise in cerebellum, brainstem and optic pathway. 
While the majority of PAs developing within the cerebellum 
harbor BRAF gene rearrangements [1], one of the most 
common genetic etiologies for optic pathway gliomas 
(OPGs) is the neurofibromatosis type 1 (NF1) inherited 
cancer syndrome. Unlike their sporadic counterparts, these 
NF1-OPGs result from bi-allelic inactivation of the NF1 
tumor suppressor gene [2–4]. However, similar to PAs 
arising in other brain locations, NF1-OPGs contain low 
proliferative indices (< 1%), and harbor both glial fibrillary 
acidic protein (GFAP)- and Olig2-immunoreactive cells [5]. 
In the context of NF1, 15–20% of individuals 
will develop an OPG, which can arise at any age during 
childhood, ranging from infancy [6] to the early teens [7]. 
Moreover, there is a considerable spectrum of anatomic 
and clinical heterogeneity. As such, NF1-OPGs can form 
anywhere along the optic pathway from the optic nerves 
to the optic radiations, and only 30–50% of children with 
NF1-OPG experience visual impairment [8] or precocious 
puberty due to hypothalamic involvement [9]. 
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Since human NF1-OPGs are rarely biopsied and 
patient-derived xenografts are unavailable, the majority 
of our insights into pathogenesis of these tumors have 
derived from the use of genetically-engineered mouse 
(GEM) strains [10, 11]. These GEM models have been 
particularly informative for preclinical therapeutic drug 
discovery and evaluation, resulting in the identification 
of mechanistic target of rapamycin and MEK as potential 
targets for optic glioma treatment [12–14], now under 
evaluation in human clinical trials.  
In addition, these GEM models have been useful 
in defining the potential cells of origin for murine optic 
glioma. In these studies, somatic Nf1 loss in BLBP+ [15] 
or GFAP+ [11] neuroglial progenitor cells that also co-
express the CD133 stem cell marker results in optic glioma 
formation by 3 months of age. However, somatic Nf1 loss 
in NG2+ cells during embryogenesis [16] or postnatal 
GFAP+ astrocytes [17] do not generate optic gliomas. In 
addition, these Nf1 GEM strains support a regional origin 
for optic glioma cells of origin to the embryonic third 
ventricle (TVZ) [17], consistent with one human study 
using gene expression profiling [18].
The prevalence of Olig2+ cells in human 
gliomas [5], coupled with recent findings that Olig2+ 
oligodendrocyte precursor cells (OPCs) are the cells 
of origin for murine malignant glioma [19], raises the 
possibility that OPCs might be another tumor-initiating 
cell population for Nf1 murine optic glioma. Herein, we 
employ two distinct Cre transgenic mouse strains, in 
which somatic Nf1 gene inactivation occurs in Olig2+ 
glial progenitor cells or CD133+ neural progenitor/stem 
cells, to demonstrate that the cell of origin is one major 
determinant in dictating the temporal course of optic 
gliomagenesis in mice. 
RESULTS AND DISCUSSION
Mouse optic gliomas harbor increased numbers 
Olig2+ cells
Previous studies in human low-grade gliomas (PAs) 
have revealed increased numbers of Olig2+ cells [5]. To 
determine whether these findings were similarly observed 
in Nf1 murine optic gliomas, we leveraged a representative 
GEM strain (Nf1flox/mut; GFAP-Cre; “FMC”), which harbors 
a germline inactivating Nf1 gene mutation, but undergoes 
somatic loss of the remaining wild-type Nf1 allele (Nf1flox 
allele) in GFAP-Cre-expressing neuroglial progenitors 
by embryonic day 14.5 (E14.5). By 3 months of age, 
~90% of FMC mice form low-grade gliomas within the 
prechiasmatic optic nerves and chiasms, characterized 
by increased proliferation, microglia infiltration, nuclear 
atypia, cellular pleiomorphism, axonal damage, and 
retinal ganglion cell death [11]. Similar to their human 
counterparts, more Olig2+ cells (1.7-fold) were found in 
FMC mouse optic gliomas relative to their non-neoplastic 
optic nerve counterparts (Figure 1A). Increased Olig2+ cell 
content was also observed in other Nf1 GEM strains with 
optic glioma (data not shown).
Somatic Nf1 loss in Olig2+ cells results in delayed 
optic glioma formation
To determine whether Olig2+ cells can generate 
astroglial cells in the optic nerve, Olig2-Cre mice were 
intercrossed with Rosa-GREEN reporter mice. The Olig2-
Cre mouse employed is a transgenic strain containing 
endogenous Olig2 promoter elements, thus fully 
recapitulating normal Olig2 expression in vivo [20]. Similar 
to the GFAP-Cre mice used to generate FMC optic gliomas, 
Olig2-Cre mice also give rise to S100β+ glia (Figure 1B) 
and GFAP+ astrocytes (data not shown). Since Olig2+ cells 
can give rise to astrocytes in the optic nerve, we next sought 
to determine whether Nf1 loss in Olig2+ cells was sufficient 
for optic glioma formation in Nf1+/− mice. 
While Nf1flox/mut; Olig2-Cre (“FMOC”) mice had larger 
optic nerve volumes relative to control littermates at 3 months 
of age (Supplementary Figure 1A), in striking contrast to 
FMC optic nerves, there was no evidence for glioma. In this 
respect, increased Iba1+ microglia and proliferation (Ki67+ 
cells) were not observed relative to control littermates 
(Figure 2). While no tumors were identified, there were 
more enlarged axons (Supplementary Figure 1B), increased 
myelin sheath thickness (Supplementary Figure 1C), and 
reduced g-ratios (Supplementary Figure 1D), similar to 
that observed following Nf1 loss in other oligodendrocyte 
lineage cells [21], as well as associated retinal pathology, 
including increased TUNEL+ labeling, decreased Brn3a+ 
retinal ganglion cells, and thinning of the retinal nerve fiber 
layer (Figure 2).  
We next sought to determine whether somatic Nf1 
loss in Olig2+ progenitors delayed the onset of glioma 
development. For this analysis, we chose to examine these 
mice at both 4.5 and 6 months of age. At 4.5 months of age, 
FMOC mice had enlarged optic nerve volumes (0.088mm3 ± 
0.016), but microglia content (%Iba1+ cells; 6.92 ± 0.5) and 
proliferation (%Ki67+ cells; 0.28 ± 0.35) were comparable 
to that observed in control mice. These results suggest that 
optic gliomas had not formed at this time point. 
However, at 6 months of age, optic nerve volumes 
in FMOC mice were increased (Figure 3), with enlarged 
axons, increased myelin sheath thickness (Supplementary 
Figure 2), and retinal pathology (Figure 3). Importantly, 
there was now a 1.8-fold increase in the percent of Iba1+ 
microglia and a 5.7-fold increase in the percent of Ki67+ 
cells relative to controls (Figure 3), indicating glioma. In 
addition, there was increased retinal apoptosis (%TUNEL+ 
cells), retinal ganglion cell loss (%Brn3a+ cells), and retinal 
nerve fiber layer thinning (SMI-32 immunostaining). 
Collectively, these data reveal that while somatic Nf1 loss 
in Olig2+ cells results in optic glioma formation, the latency 
is extended relative to FMC mice [11]. 
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Delayed optic gliomagenesis reflects distinct cells 
of origin
One possible interpretation for the delay in glioma 
formation is the timing or brain location of somatic Nf1 
loss in FMOC mice relative to FMC mice. However, the 
Olig2-Cre transgene was expressed by E12, similar to 
previously-employed Nf1 optic glioma GEM models [15], 
labeling cells along the lateral (data not shown) and third 
ventricles where Sox2+ progenitors reside (Figure 4A). 
Next, we performed lineage tracing of the cells of 
origin in these mouse strains, leveraging Rosa-GREEN 
reporter mice intercrossed with GFAP-Cre and Olig2-Cre 
mice, respectively. Within the optic nerves both GFAP-
Cre x Rosa-GREEN and Olig2-Cre x Rosa-GREEN 
mice contained EGFP+ cells that co-labeled with S100β 
(Figure 1C) or Sox2 (Figure 4B). In contrast, EGFP/Olig2+ 
cells were only found in the optic nerves of Olig2-Cre x 
Rosa-GREEN mice (Figure 4C). The fact that the GFAP-
Cre transgene does not generate Olig2+ cells suggests that 
the cells of origin for FMOC optic gliomas are distinct 
from those that give rise to FMC optic gliomas. 
Finally, to demonstrate that the cell of origin is a 
major determinant underlying the observed differences 
in tumor latency, we employed a Cre transgenic strain in 
which Nf1 loss could be specifically induced in CD133+ 
neural progenitor/stem cells at a similar time as occurs 
in FMC mice. The prominin1-CreER strain contains a 
tamoxifen-regulated Cre recombinase protein expressed 
from the endogenous prominin-1 (CD133) promoter 
[22], thus targeting neural stem cells in the brain [23] 
expressing GFAP [24]. As such, optic nerves from Prom1-
CreER x Rosa-GREEN mice injected with tamoxifen 
and progesterone at E15 contained EGFP+ cells that co-
labeled with S100β and Sox2, but not Olig2, similar to 
that observed with GFAP-Cre x Rosa-GREEN mice (data 
not shown). 
Based on these findings, we generated 
Nf1flox/mut; Prom1-CreER (FMPrC) mice for tamoxifen 
and progesterone injection at E15. At 3 months of 
age, FMPrC mice had increased optic nerve volumes, 
percentages of Iba1+ cells, and percentages of Ki67+ 
cells (Figure 5), similar to that observed with FMC 
mice. In addition, these mice had clear retinal pathology, 
with increased retinal cell apoptosis (%TUNEL+ cells), 
reduced retinal ganglion cell numbers (%Brn3a+ cells), 
and decreased retinal nerve fiber layer thickness (SMI-
32 immunostaining). These results indicate that somatic 
Nf1 inactivation in neural progenitor/stem cells (GFAP+ 
or CD133+ cells) results in gliomagenesis at 3 months of 
age, whereas Nf1 loss in Olig2+ cells generates tumors 
with a prolonged latency. While the cell lineage tracing 
experiments using Rosa-GREEN strains demonstrate that 
Olig2+ cells in the optic nerve do not arise from CD133+ 
or GFAP-Cre transgene-expressing cells at E15–16, 
future studies will be required to identify the specific 
subpopulations of progenitors cells capable of serving as 
the potential cells of origin for these tumors.
Figure 1: Mouse optic gliomas harbor increased numbers of Olig2+ cells. (A) 3-month-old FMC optic gliomas exhibit a 
1.7- fold increase in the percentage of Olig2+ cells relative to non-neoplastic optic nerves. Error bars, mean ± SEM. **p = 0.0011. (B) Optic 
nerves from Rosa-GREEN x GFAP-Cre and Olig2-Cre mice, respectively, reveal EGFP+/S100β+ glia. Representative images include insets 
of immunopositive cells (arrows). Scale bar, 10 µm. 
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Figure 2: FMOC mice do not develop optic gliomas at 3 months of age. FMOC mice have increased cellularity (hematoxylin/
eosin) compared to controls (n = 5 mice/group). No change in the percentage of Ki67+ or Iba1+ cells was observed. There was increased 
retinal cell apoptosis (%TUNEL+ cells), fewer Brn3a+ cells, and reduced retinal nerve fiber layer (RNFL) thickness in FMOC mice relative 
to controls. Nuclei were counterstained with DAPI (blue). Representative images include insets of immunopositive cells (arrows). Scale 
bar, 100 µm. Error bars, mean ± SEM. ***p < 0.0003; **p = 0.0078; N.S. = not significant
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Figure 3: FMOC mice develop optic glioma by 6 months of age. FMOC mice have larger optic nerve volumes relative to controls 
as well as increased cellularity (hematoxylin/eosin) (n = 5 mice/group). 6-month-old FMOC mice show increased percentages of Ki67+ and 
Iba1+ cells. There was also increased retinal cell apoptosis (%TUNEL+ cells), fewer Brn3a+ cells, and reduced RNFL thickness in FMOC 
mice. Nuclei were counterstained with DAPI (blue). Representative images include insets of immunopositive cells (arrows). Scale bar, 
100 µm. Error bars, mean ± SEM. ***p < 0.0006; **p = 0.0038; *p = 0.049. 
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The impact of the cell of origin on the temporal 
course of gliomagenesis
Taken together with our previous studies showing 
that Nf1+/− mice with somatic Nf1 loss in NG2+ cells do 
not form optic gliomas [16], we now conclude that both 
neuroglial progenitor cells (GFAP+, BLBP+, CD133+ cells) 
and pre-OPCs (Olig2+, NG2neg cells) can serve as initiating 
cells for murine Nf1 low-grade glioma, but with different 
latencies to tumor formation [25]. As such, Nf1+/− mice 
with somatic Nf1 inactivation in GFAP-Cre+ [11], BLBP+ 
[15], or CD133+ neural stem cells all develop tumors by 
Figure 4: Cells of origin for FMOC optic gliomas are distinct from those that give rise to FMC mouse optic gliomas. 
(A) Olig2+ cells line the third ventricular surface as early as E11.5. Sox2 expressing cells are located in the same region within the third 
ventricle at E11.5 as Olig2+ cells. (B) Optic nerve sections from Rosa-GREEN x GFAP-Cre and Olig2-Cre mice at 3 weeks of age, 
respectively, contain both EGFP/Sox2 double-positive cells. (C) In contrast, EGFP/Olig2+ cells are only found in the optic nerves of Rosa-
GREEN x Olig2-Cre mice, but not in those from Rosa-GREEN x GFAP-Cre mice, at 3 weeks of age. Representative images are shown with 
insets of immunopositive cells. Arrowheads indicate single positive cells, whereas arrows indicate double-positive cells.
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Figure 5: Somatic Nf1 loss in neural stem cells recapitulates the temporal course of optic gliomagenesis observed 
in FMC mice. FMPrC mice have larger optic nerve volumes relative to controls, as well as increased cellularity (hematoxylin/eosin) 
(n = 5 mice/group). 3-month-old FMPrC mice show increased percentages of Ki67+ and Iba1+ cells. There was also increased retinal cell 
apoptosis (%TUNEL+ cells), fewer Brn3a+ cells, and reduced RNFL thickness in FMPrC mice. Nuclei were counterstained with DAPI 
(blue). Representative images include insets of immunopositive cells (arrows). Scale bar, 100 µm. Error bars, mean ± SEM. ***p < 0.0003; 
**p = 0.0079; *p = 0.0429.
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3 months of age, whereas those with Nf1 inactivation in 
pre-OPCs form gliomas later. Since neither GFAP-Cre 
nor prominin-1-CreER mice treated with tamoxifen at E15 
generate Olig2+ cells, yet all Cre driver lines give rise 
to GFAP+ and S100β+ macroglial cells, we propose that 
Olig2+ cells represent a glial precursor lineage distinct 
from those delineated by GFAP-Cre- or prominin-1-CreER-
mediated somatic Nf1 loss. These findings suggest that 
there are multiple distinct cells of origin for glioma that 
each can generate astrocytes through unique differentiation 
pathways. Consistent with this hypothesis, whole-tumor 
RNA-sequencing analyses of FMC and FMOC optic 
gliomas demonstrates that these two brain tumors are 
molecularly-distinct entities [26]. 
While the studies herein are novel with respect to 
low-grade glioma, they join a growing body of evidence 
that suggests that the cell of origin is critical for creating 
the diversity of human cancers. As such, whereas luminal 
and basal cells can both serve as cells of origin for prostate 
cancer, each generates distinct subtypes with different 
histological and molecular features [27]. Similarly, CD133-
negative luminal cells give rise to highly metastatic breast 
cancers, but CD133-positive luminal cells generate both 
basal and luminal tumors with little metastatic potential 
[28]. Finally, dorsal brainstem progenitor cells are the 
cells of origin for one subtype of medulloblastoma, 
while cerebellar granule precursors are responsible for a 
different subtype of this common pediatric brain tumor, 
each with different molecular properties [29]. Although 
these reports highlight the ways in which the cell of origin 
creates molecular tumor diversity, our findings demonstrate 
that histologically-similar tumors can be generated with 
different latencies based entirely on their progenitor 
cell origins. Future studies aimed at characterizing the 
different responsible progenitor cell populations may yield 
important insights into the diversity of cellular origins of 
pediatric glioma relevant to the clinical spectrum of OPGs 
encountered in children with NF1.
MATERIALS AND METHODS
Mice
 Nf1+/− mice [30] were bred with Nf1f/wt mice to 
produce Nf1flox/mut mice, and intercrossed with Nf1flox/flox; 
Olig2-Cre mice to generate Nf1flox/mut; Olig2-Cre (FMOC) 
mice, while Nf1flox/mut; GFAP-Cre (FMC; [11]) and Nf1flox/
flox [31] control mice were established as previously 
reported. Nf1flox/mut mice were also intercrossed with 
Nf1flox/flox; Prom1-CreER mice [22] to generate Nf1flox/mut; 
Prom1-CreER (FMPrC) mice. Timed-pregnant FMPrC 
dams (gestational day 14–16) underwent oral gavage with 
1mg tamoxifen (Sigma-Aldrich, St. Louis, MO) and 1 mg 
progesterone (Sigma-Aldrich, St. Louis, MO) in 100µl of 
corn oil suspension. Olig2-Cre mice (B6-Olig2tm2 (TVA,cre)
Rth/J; Jackson Laboratory; [20]) and GFAP-Cre mice 
[32] were intercrossed with Rosa-GREEN mice (B6.Cg-
Gt(ROSA)26Sortm(CAGZsGreen1)Hze+/J; Jackson Laboratory) for 
cell fate mapping. Mice were backcrossed and maintained 
on a C57Bl/6 background and used in accordance with 
approved Animal Studies protocols. The recombination 
frequency of Olig2-Cre (11.11%; data not shown) 
and GFAP-Cre (13.36%; [16]) mice were determined 
following intercrossing with Rosa-GREEN mice.
Immunohistochemistry
 Paraffin and frozen section immunohistochemical 
analyses were performed [33] using specific antibodies 
(Supplementary Table 1), followed by either Alexa-Fluor-
tagged secondary antibodies (Invitrogen, Grand Island, 
NY) and DAPI counterstaining or biotinylated secondary 
antibodies and Vectastain Elite ABC development. 
Terminal deoxynucleotide transferase-mediated dUTP 
nick-end labeling (TUNEL) staining was performed as 
before [33]. 
Optic nerve measurements
 Optic nerves with an intact chiasm were 
microdissected, photographed, and optic nerve volumes 
calculated [13].
Statistical analysis
Statistical analysis was performed as previously 
described [33].
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